IgA Nephropathy Foundation Launches Kidney Month Campaign Elevating Patient Voices and New Education Resources

The campaign features newly published research from Board members living with IgAN, alongside new educational resources ...
STAT

Vertex says its drug successfully reduced marker of kidney disease in late-stage trial

Vertex said a drug it secured as part of a $4.9 billion acquisition successfully reduced by half a key marker of a kidney ...
Everyday Health on MSN

IgA nephropathy (IgAN) fatigue: 7 tips and management strategies

Fatigue is a common side effect of IgA nephropathy (IgAN). Learn how to address causes, from anemia and poor sleep to dietary and medication issues.
Healthline

What’s the Outlook for IgA Nephropathy (Berger’s Disease)? Your FAQs

Immunoglobulin A (IgA) nephropathy is an autoimmune condition that causes inflammation and damage in your kidneys, which may lead to kidney failure over time. IgA nephropathy develops when IgA builds ...
BioPharma Dive

Vertex kidney disease drug hits mark in late-stage study

Company shares surged in after-market trading on results for a drug Vertex acquired in a multibillion-dollar deal and sees as ...
Stocktwits on MSN

VRTX soars in extended hours after experimental drug shows positive changes in autoimmune kidney disease

Shares of Vertex Pharmaceuticals Incorporated (VRTX) rose as much as 7% after hours on Monday after the company announced ...
The American Journal of Managed Care

Rethinking KDIGO Guidance and Payer Models in the Era of Targeted IgA Nephropathy Therapies

This episode, titled Rethinking KDIGO Guidance and Payer Models in the Era of Targeted IgA Nephropathy Therapies, features expert nephrologists discussing the following critical questions: What ...
MedPage Today

FDA OKs Complement Inhibitor for IgA Nephropathy

The FDA granted accelerated approval to iptacopan (Fabhalta) for primary immunoglobulin A (IgA) nephropathy, a rare progressive disease where the immune system attacks the kidneys, Novartis announced ...